Fig. 2
From: A medium-chain fatty acid analogue prevents endotoxin liver injury in a murine model
(A) Body weights, (B) Parenteral nutrition consumption, and (C) Normalized organ weights of liver, spleen, and kidney by treatment group over the course of a 19-day experiment involving a murine model of parenteral nutrition-associated liver disease. For (A) and (B), treatment groups are named in the following order: ad libitum oral intake (PN vs. chow), intravenous injection (saline vs. Intralipid), oral gavage (MCT vs. SEFA), and intraperitoneal treatment (saline vs. LPS). Mean ± Standard Error of Mean. PN, parenteral nutrition; SEFA, structurally engineered fatty acid (i.e. SEFA-6179); MCT, medium-chain triglyceride; LPS, lipopolysaccharide.
